Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:

The good — FDA approves Akebia Therapeutics' Vafseo anemia drug

The bad — Bristol Myers Squibb's Crohn's disease drug disappoints 
The ugly — FDA rejects Regeneron Pharmaceuticals lymphoma treatment